All Phenotypes Ern1<tm1Rjk> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Ern1^tm1Rjk/Ern1^tm1Rjk	involves: 129S1/Sv * 129X1/SvJ	MGI:3723591
hm2	Ern1^tm1Rjk/Ern1^tm1Rjk	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	MGI:3625033
cn3	Ern1^tm1Rjk/Ern1^tm2.1Rjk Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA	MGI:4949418

Allelic Composition	Ern1^tm1Rjk/Ern1^tm1Rjk
Genetic Background	involves: 129S1/Sv * 129X1/SvJ

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ern1^tm1Rjk mutation (0 available); any Ern1 mutation (58 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

abnormal cell physiology ( J:124971 )

• expression of one unfolded protein response target genes, Edem, is decreased in mouse embryonic fibroblasts stressed with tunicamycin or thapsigargin results

Allelic Composition	Ern1^tm1Rjk/Ern1^tm1Rjk
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ern1^tm1Rjk mutation (0 available); any Ern1 mutation (58 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:106975 )

• homozygous embryos die around E10.5

• Background Sensitivity: by backcrossing these heterozygotes further onto C57BL/6J, homozygous embryos which survive to E12.5-13 are produced

embryo

embryonic growth retardation ( J:106975 )

• at E13 homozygotes exhibit growth retardation

decreased embryo size ( J:106975 )

• by E13 homozygotes can be recognized by their small size

growth/size/body

embryonic growth retardation ( J:106975 )

• at E13 homozygotes exhibit growth retardation

decreased embryo size ( J:106975 )

• by E13 homozygotes can be recognized by their small size

hematopoietic system

abnormal definitive hematopoiesis ( J:106975 )

• hematopoietic cells from null mice have a 2.5-fold lower rate of proliferation than the rate of heterozygous cell proliferation

abnormal pro-B cell morphology ( J:106975 )

• Ern1-null pro-B cells are defective in VDJ recombination of immunoglobulin genes and do not express B cell receptors

immune system

abnormal pro-B cell morphology ( J:106975 )

• Ern1-null pro-B cells are defective in VDJ recombination of immunoglobulin genes and do not express B cell receptors

liver/biliary system

liver hypoplasia ( J:106975 )

• at E12.5, homozygous fetal livers are markedly reduced in size compared to wild-type

integument

pallor ( J:106975 )

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

increased hepatocyte apoptosis ( J:171230 )

• 5-times in response to Bortezomib treatment

increased liver triglyceride level ( J:171230 )

• following tamoxifen treatment

• following partial hepatectomy

• in response to Bortezomib treatment

abnormal hepatocyte morphology ( J:171230 )

• liver cells exhibit less rough endoplasmic reticulum content compared with control liver cells

hepatic steatosis ( J:171230 )

• mice exhibit a slight increase in hepatic lipid content compared with control mice

• mice subjected to liver stress (partial hepatectomy or treatment with tamoxifen or Bortezomib) exhibit increased accumulation of lipids in the liver compared with control mice

• however, phospholipid synthesis is normal

homeostasis/metabolism

abnormal lipid level ( J:171230 )

• mice exhibit a slight increase in hepatic lipid content compared with control mice

• mice subjected to liver stress (partial hepatectomy or treatment with tamoxifen or Bortezomib) exhibit increased accumulation of lipids in the liver compared with control mice

• however, phospholipid levels in the liver are normal

decreased circulating cholesterol level ( J:171230 )

• following tamoxifen-treatment